Cours RXi Pharmaceuticals Corp Nasdaq
Actions
US74979C8082
Recherche biotechnologique et médicale
CA 2024 * | - | CA 2025 * | 75 M 68,41 M | Capitalisation | 3,51 M 3,2 M |
---|---|---|---|---|---|
Résultat net 2024 * | -9 M -8,21 M | Résultat net 2025 * | 47 M 42,87 M | VE / CA 2024 * | - |
Trésorerie nette 2024 * | - 0 | Trésorerie nette 2025 * | - 0 | VE / CA 2025 * | 0,05 x |
PER 2024 * |
-0,42
x | PER 2025 * |
0,2
x | Employés | - |
Rendement 2024 * |
-
| Rendement 2025 * |
-
| Flottant | 99,5% |
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Robert Bitterman
CEO | Chief Executive Officer | 73 | 19/06/12 |
Caitlin Kontulis
DFI | Director of Finance/CFO | - | - |
James Cardia
CTO | Chief Tech/Sci/R&D Officer | - | 15/09/17 |
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Robert Bitterman
CEO | Chief Executive Officer | 73 | 19/06/12 |
Director/Board Member | 73 | 02/05/22 | |
Curtis Lockshin
BRD | Director/Board Member | 64 | 18/04/13 |
Varia. 1 janv. | Capi. | |
---|---|---|
+52,64% | 63,85 Md | |
-2,50% | 41,83 Md | |
+40,01% | 40,47 Md | |
-10,22% | 27,17 Md | |
+13,41% | 26,52 Md | |
-21,46% | 18,69 Md | |
+2,79% | 12,73 Md | |
+22,32% | 12,11 Md | |
+27,78% | 12,07 Md |